Trimer stabilizing hiv envelope protein mutations
AssigneeJanssen Vaccines & Prevention B.V.
InventorsLucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes P. M. Langedijk
Life of this patent
Estimating the term…
Loading patent…
AssigneeJanssen Vaccines & Prevention B.V.
InventorsLucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes P. M. Langedijk
Estimating the term…
Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.
An isolated nucleic acid molecule encoding a recombinant human immunodeficiency virus (HIV) envelope (Env) protein comprising two or more of the following amino acid residues:
An isolated nucleic acid encoding a recombinant human immunodeficiency virus (HIV) envelope (Env) protein comprising one or more of the following amino acid residues:
An isolated nucleic acid molecule encoding a recombinant human immunodeficiency virus (HIV) envelope (Env) protein comprising one or more of the following amino acid residues:
Dependencies are inferred from the claim text.